Mark Hyman, MD · 2026-07-01 · Mark Hyman (host), Cindy Geyer, Aseem Malhotra, Eric Topol
It's Not Cholesterol. Inflammation Is What's Actually Causing Heart Disease
48 research-tied claims examined: 6 contradicted 6 overstated 1 context 34 supported 1 unverified
6 Contradicted by research
Small HDL particles are less capable of clearing LDL particles and facilitating reverse cholesterol transport than larger HDL particles.
"The same is true for HDL. We've historically thought of HDL as being the good, healthy cholesterol, but size matters there, too. Small HDL doesn't seem to be as able to cart out the bad LDL and get rid of it." (said at 0:10:12)
The speaker states the relationship between HDL particle size and cholesterol removal backwards. In reverse cholesterol transport, small, dense HDL particles (such as discoidal HDL and pre-beta HDL) are the primary and most potent mediators of cellular cholesterol efflux via the ABCA1 (ATP-binding cassette transporter A1) pathway. Experimental and clinical studies consistently demonstrate that cholesterol efflux capacity increases as HDL particle size decreases, with small HDL particles displaying 3- to 5-fold greater efflux capacity than larger HDL subfractions.
The JUPITER trial and related studies showed that patients with high LDL cholesterol but low C-reactive protein have a negligible risk of cardiovascular disease compared to those with both high LDL and high CRP.
"A lot of the follow-up studies, like the JUPITER trial, they found that if patients had a high LDL but they didn't have a high CRP, their risk of heart disease was negligible. But if they had a high LDL and a high CRP, that was the problem." (said at 0:12:45)
The speaker misrepresents both the design of the JUPITER trial and the findings of studies evaluating LDL cholesterol and C-reactive protein (CRP). The JUPITER trial (Ridker et al., 2008) specifically enrolled individuals with low/normal LDL cholesterol (<130 mg/dL) and elevated hs-CRP (≥2.0 mg/L) to evaluate statin therapy in low-cholesterol, high-inflammation individuals; it did not evaluate participants with high LDL and low CRP. Furthermore, large cohort studies examining both biomarkers (such as Ridker et al., 2002) demonstrate that baseline LDL cholesterol and hs-CRP are independently and linearly associated with cardiovascular event risk; cardiovascular risk in individuals with high LDL cholesterol is not 'negligible' even when CRP levels are low.
In the Framingham Heart Study data summarized by William Castelli in 1996, LDL cholesterol was useless as a predictor of coronary artery disease unless LDL was above ~7.8 mmol/L (~250 mg/dL).
"William Castelli is a cardiologist, and he published—uh, he was a co-director of Framingham, and in 1996 he published in one of the cardiology, major cardiology journals, a summary of Framingham specifically looking at LDL cholesterol. ... And he said from Framingham, unless your LDL was above 7.8, 8 millimoles, which by the way, I think in your units is probably 250 or 300, 250 probably. ... It absolutely had no—it was useless as a predictor for coronary artery disease." (said at 0:47:11)
In his 1996 review summarizing Framingham Heart Study insights on lipid risk factors, William Castelli did not state that LDL cholesterol was useless as a predictor of coronary artery disease below ~7.8 mmol/L (~300 mg/dL). Rather, Castelli identified abnormal lipids (including atherogenic low-density lipoproteins) as one of the three primary cardiovascular risk factors, while noting that because most coronary heart disease events occur in individuals with average total cholesterol levels (overlap between cases and non-cases), assessing isolated total cholesterol or LDL without HDL is insufficient. He advocated for using the total cholesterol-to-HDL cholesterol ratio and triglyceride levels to more effectively identify patients at high risk who require treatment.
- contradicts: Lipids, risk factors and ischaemic heart disease. (Atherosclerosis 1996) · cited 327x in the literature
"Among these, the three most important are (1) abnormal lipids, including the fact that there are more than 15 types of cholesterol-containing lipoproteins and four different types of triglyceride-rich particles, some of which are very atherogenic, (2) high blood pressure, and (3) cigarette smoking... Firstly, the ratio of total cholesterol to high density cholesterol (HDL cholesterol) should be determined, followed by measurement of plasma triglyceride concentrations. This will allow differentiation of whether the low density lipoproteins (LDL), HDL cholesterol or triglyceride-rich particles such as the small dense beta-very low density lipoproteins (VLDL) are the major cause for concern." (abstract, results, passage verified)
pubmedfull study (doi)
When corrected for triglyceride and HDL levels, LDL cholesterol loses statistical significance as a predictor of heart disease.
"When you correct for triglycerides and HDL, okay, which by the way is a more important predictor of heart disease, LDL loses its significance completely." (said at 0:48:10)
Large-scale prospective cohort studies and individual-participant meta-analyses demonstrate that LDL cholesterol (LDL-C) and atherogenic apoB-containing particles remain statistically significant, independent predictors of coronary heart disease (CHD) after multivariable adjustment for HDL cholesterol and triglycerides. In the Emerging Risk Factors Collaboration analysis of 302,430 individuals across 68 prospective studies, directly measured LDL-C remained significantly associated with CHD risk even after adjustment for conventional risk factors including HDL-C and triglycerides (hazard ratio 1.38 per 1-SD increase, 95% CI 1.09–1.73). In fact, the inverse of the guest's claim occurred for triglycerides: after adjusting for HDL-C and non-HDL-C/LDL-C, triglycerides lost independent statistical significance for CHD (adjusted HR 0.99, 95% CI 0.94–1.05).
- contradicts: Major lipids, apolipoproteins, and risk of vascular disease. (JAMA 2009) · cited 2789x in the literature
"Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C... For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C." (abstract, results)
pubmedfull study (doi)
In the JUPITER trial, individuals with high LDL cholesterol but low inflammatory markers had lower cardiovascular risk than those with both high LDL and high inflammation.
"In fact, Paul Ridker from Harvard, I remember he published a trial, I think it was the JUPITER trial, where they showed that if you had a high LDL but didn't have any inflammation, you didn't have that significant a risk of having heart disease. But if you had a high level of inflammation, high LDL, you had a much higher risk." (said at 0:56:58)
The host's description of the JUPITER trial is contradicted by the trial's actual inclusion criteria and design. The JUPITER trial, led by Paul Ridker, specifically enrolled individuals with low-to-modest LDL cholesterol (<130 mg/dL) and elevated high-sensitivity C-reactive protein (hs-CRP ≥2 mg/L). The study did not evaluate or include patients with high LDL cholesterol and low inflammatory markers, and therefore did not demonstrate that high LDL in the absence of inflammation carries low cardiovascular risk.
The World Health Organization officially declared obesity a global epidemic in 2004.
"So 2004, WHO announced it as an epidemic." (said at 0:42:30)
The World Health Organization (WHO) officially recognized and declared obesity as a global epidemic in June 1997 during the WHO Consultation on Obesity in Geneva, rather than in 2004. The conclusions and recommendations of this landmark meeting were published in the WHO Technical Report Series under the title "Obesity: preventing and managing the global epidemic" (PMID 11234459). While the World Health Assembly adopted the Global Strategy on Diet, Physical Activity and Health in 2004, the formal declaration of the obesity epidemic itself occurred seven years earlier.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.